GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » 3-Year FCF Growth Rate

Applied Therapeutics (Applied Therapeutics) 3-Year FCF Growth Rate : 43.10% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics 3-Year FCF Growth Rate?

Applied Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.15.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 43.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Applied Therapeutics was 43.10% per year. The lowest was -116.90% per year. And the median was -16.35% per year.


Competitive Comparison of Applied Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Applied Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's 3-Year FCF Growth Rate falls into.



Applied Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Applied Therapeutics  (NAS:APLT) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Applied Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Therapeutics (Applied Therapeutics) Business Description

Traded in Other Exchanges
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.
Executives
Stacy J. Kanter director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman director, 10 percent owner, officer: President and CEO C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard officer: Chief Commercial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti officer: Chief Medical Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc. 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe officer: Chief Accounting Officer 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan officer: Chief Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega officer: Principal Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler director DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173

Applied Therapeutics (Applied Therapeutics) Headlines

From GuruFocus

Applied Therapeutics Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023